GO:0097161 DH domain binding: Mechanism, Genes and Research

GO:0097161, DH domain binding, is a molecular function that describes the binding of a protein to a DH (Dbl homology) domain of another protein. The DH domain is a structurally conserved module composed of 11 alpha helices folded into a flattened, elongated alpha-helix bundle, with conserved regions CR1 and CR3 exposed near the center of one surface. This domain is best known as the catalytic unit of Dbl-family guanine nucleotide exchange factors (GEFs), which activate Rho-family GTPases by promoting the exchange of GDP for GTP. Understanding DH domain binding is therefore central to deciphering how extracellular signals are transduced into cytoskeletal rearrangements, cell migration, and proliferation. Researchers study DH domain binding to uncover how GEFs achieve specificity toward particular Rho GTPases and how mutations in DH domains alter signaling in human disease. For example, mutations in the DH domain of TRIO, a multidomain GEF, lead to opposite effects on RAC1 activity and are associated with distinct neurodevelopmental disorders. This makes DH domain binding a focal point for both basic cell biology and translational research in cancer and neurodevelopment. The term is also important for understanding how protein-protein interactions at the DH domain interface can be targeted pharmacologically. Because the Rho GTPase interacting pocket is formed by CR1, CR3, part of alpha-6, and the DH/PH junction, small molecules or peptides that bind this surface could modulate GEF activity. Thus, DH domain binding represents a convergence point for structural biology, signal transduction, and therapeutic development.

DH domain binding (GO:0097161) is the molecular function of selectively interacting with a DH (Dbl homology) domain of a protein. The DH domain contains three structurally conserved regions separated by more variable regions and is composed of 11 alpha helices folded into a flattened, elongated alpha-helix bundle. Two of the conserved regions, CR1 and CR3, are exposed near the center of one surface, and together with part of alpha-6 and the DH/PH junction site, they constitute the Rho GTPase interacting pocket. Binding to this domain can modulate GEF activity or recruit signaling effectors.

DH domain binding is important because DH domains are the catalytic cores of Dbl-family GEFs that activate Rho GTPases, which control fundamental processes such as cytoskeletal dynamics, cell migration, proliferation, and differentiation. Dysregulation of these interactions contributes to cancer progression and neurodevelopmental disorders, as exemplified by TRIO mutations that oppositely modulate RAC1 and cause domain-specific disease phenotypes. Studying DH domain binding therefore provides mechanistic insight into signal transduction and offers potential targets for therapeutic intervention.

The following genes encode proteins that contain DH domains or are known to bind DH domains, and they are frequently studied in the context of GO:0097161.

DH domain binding is regulated at multiple levels. Intramolecular autoinhibition is common in Dbl-family GEFs, where the DH domain is masked by other domains or by phosphorylation, preventing premature GTPase activation. Phosphoinositide binding to the adjacent PH domain can relieve autoinhibition and recruit GEFs to membranes, thereby promoting DH domain engagement with GTPases. Post-translational modifications such as phosphorylation and ubiquitination also modulate GEF activity and stability. In TRIO, mutations in the DH domain alter its regulation of RAC1, leading to opposite effects on GTPase activity depending on the specific mutation.

Mutations in the DH domain of TRIO are associated with distinct neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. These mutations can oppositely modulate RAC1 activity, leading to either gain-of-function or loss-of-function effects that disrupt neuronal development. The domain-specific nature of these mutations highlights the importance of DH domain binding in brain development.

DH-domain-containing GEFs such as PREX1, PREX2, and VAV proteins are frequently dysregulated in cancer, where they promote cell migration, invasion, and metastasis through aberrant Rho GTPase activation. Targeting DH domain interactions is being explored as a therapeutic strategy to inhibit oncogenic GEF activity.

DH domain binding is critical for immune cell signaling, as GEFs like VAV1 and ARHGEF1 regulate lymphocyte activation and migration. Dysregulation of these interactions can contribute to autoimmune diseases and immunodeficiencies.

In vitro binding assays such as GST pull-down, co-immunoprecipitation, and isothermal titration calorimetry can directly measure DH domain binding affinity and specificity. These methods use purified DH domain and candidate binding partners to quantify interactions.

X-ray crystallography and cryo-electron microscopy can resolve the three-dimensional structure of DH domain complexes, revealing the atomic details of the Rho GTPase interacting pocket. Such studies inform mutational analysis and drug design.

Rho GTPase activation can be monitored using pull-down assays with GTPase-binding domains or FRET-based biosensors in live cells. These assays link DH domain binding to downstream signaling events.

CRISPR-Cas9 knockout, point mutation, and knock-in models allow researchers to test the function of specific DH domain residues in a physiological context. Pooled CRISPR screens can identify modifiers of DH domain-dependent phenotypes.

Researchers studying DH domain binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling functional validation of DH domain interactions and their downstream effects.

GO:0097161 DH domain binding is a fundamental molecular function that governs Rho GTPase activation through Dbl-family GEFs. Its structural basis, centered on the Rho GTPase interacting pocket, explains how mutations can lead to diseases such as neurodevelopmental disorders and cancer. Continued research using CRISPR models and biochemical assays will further illuminate the regulatory mechanisms and therapeutic potential of targeting DH domain interactions.